Weight loss jabs may dull alcohol's effects—but at what cost?

Weight loss jabs, such as Wegovy and Mounjaro, are growing in popularity across the UK and Germany. These drugs, known as GLP-1 receptor agonists, mimic a hormone that controls hunger and blood sugar. But their use comes with strict rules—and some unexpected side effects.

The medications work by suppressing appetite, slowing digestion, and boosting insulin production. This helps lower blood sugar while reducing cravings and blocking the feel-good hormones triggered by snacking. In Germany, however, statutory health insurance does not cover Wegovy for weight loss, classifying it as a lifestyle drug rather than a medical necessity.

A recent study revealed another effect: patients on these jabs felt less tipsy and absorbed alcohol more slowly. Their breath alcohol levels rose at a reduced rate compared to those not taking the medication. Researchers now suggest the drugs could help heavy drinkers cut back by dulling alcohol's impact.

Access to these treatments varies. In the UK, NHS prescriptions are limited to specialist clinics, targeting patients with a BMI of 30 or above and a weight-related condition. Private prescribers, meanwhile, offer the jabs to anyone obese or overweight with a health risk—after a video or in-person consultation.

Yet concerns remain. As of January 2025, UK authorities investigated 85 suspected deaths linked to the drugs. Common side effects include gut problems, altered taste, and kidney issues. Rare but severe cases involve allergic reactions or acute pancreatitis.

The jabs continue to be prescribed under strict conditions, with ongoing research into their broader effects. While they may help some reduce alcohol intake, their risks and limited insurance coverage keep access tightly controlled. Officials and prescribers are monitoring their long-term impact closely.